Share our Story
Learn about our Company
ABOUT 3BL Media, LLC
3BL Media provides a cloud-based, multi-channel news and content distribution platform for innovative companies.
Journalists, investors, customers and other stakeholders now have more choices than ever as to where and how they get their news and information. From email to news terminals to social media platforms and web portals, many options are available. And different people respond differently to various message formats: blogs vs. press releases vs. videos vs. articles.
3BL Media clients know that distributing multiple message formats, through multiple channels, produces results.
The Distribution Revolution(tm) means that organizations can distribute their press releases, blogs, videos and other media assets through social media, new media and traditional media channels, creating the greatest opportunity for the target audience to encounter and interact with your content.
VC Funding for New Digital Health Startups Increases 70%; Coca-Cola to Distribute Medicine; New Kaiser Permanente Study Confirms Overall Safety of Virus Vaccination for Women - Health Minute for October 9, 2012
Venture capital funding for digital health is up by 70 percent, according to a new report from health start up accelerator Rock Health. $1.08 billion has been invested in digital health start ups so far this year, already passing the total of $956 million spent in all of last year. 84 percent more deals have been made, while 10 percent of the funds are first-time health investors.
Coca-Cola plans to distribute essential medicines and nutritional supplements to doctors and families in the developing world through its global distribution system. The company’s ColaLife project uses thin, padded, and insulated packs to ship the medical and health products on top of soft-drink bottles in crates.
A new study of 200,000 women and girls, authored by Nicola Klein, co-director and research scientist at the Kaiser Permanente Vaccine Study Center, concludes that females who receive the human papilloma virus vaccine are vulnerable to same-day fainting and skin infections only within two weeks after vaccination. The study of 200,000 women confirmed the overall, longer-term safety of the vaccination process following routine administration.
For more information on these and other stories, go to 3blmedia.com